1. Epidemiologisches Bulletin 20/2009, Virushepatitis B, C und D im Jahr 2009. Robert-Koch-Institut 2009.
2. Weltgesundheitsorganisation (WHO)
3. Schreier, E., et al., Gesundheitsberichterstattung des Bundes. Hepatitis C. Robert-Koch-Institut Juni 2003. 15
4. Empfehlung des Bundesinstitutes für Risikobewertung. Ergänzung zu den Empfehlungen der Nationalen Stillkommission zu Hepatitis C und Stillen vom März 2001. Bundesgesundheitsblatt 2003. 46: p. 790
5. EASL International Consensus Conference on hepatitis C, Paris, 26 –27 February 1999, Consensus statement. J Hepatol 1999. 31(Suppl1): p. 3–8
6. Lindenbach, B.D., et al., Flaviviridae: the viruses and their replication. p. 1101-1152.
In B.N. Fileds, D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B.
Roizman, and S.E. Straus (ed.), Fields virology 5th ed. Lippincott, Williams and Wilkins, Philadelphia PA, 2007.
7. Souci, S.W., et al., Die Zusammensetzung der Lebensmittel. Nährwert-Tabellen.
Medpharm Scientific Publishers, Ed. 5.; 1994
8. Ciesek, S., et al., Environmental stability of hepatitis C virus and its susceptibility towards chemical biocides. Journal of Infectious Diseases, 2010. In press
9. Schmidt, H., Studies on the inactivation of complement by shaking. J Hyg (Lond), 1914. 14(4): p. 417–436.
10. Mastromatteo, A.M., et al., Hepatitis C virus infection: other biological fluids than blood may be responsible for intrafamilial spread. Hepatogastroenterology, 2001.
48(37): p. 193-6.
11. Wang, J.T., et al., Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses. J Med Virol, 1992. 36(1):
p. 28-31.
12. Bourlet, T., et al., Detection and characterization of hepatitis C virus RNA in seminal plasma and spermatozoon fractions of semen from patients attempting medically assisted conception. Journal of Clinical Microbiology, 2002. 40(9): p. 3252-5.
13. Tang, Z., et al., [Detection and significance of HCV RNA in saliva, seminal fluid and vaginal discharge in patients with hepatitis C]. J Tongji Med Univ, 1996. 16(1): p.
11-3, 24.
14. Lock, G., et al., Hepatitis C - contamination of toothbrushes: myth or reality? J Viral Hepat, 2006. 13(9): p. 571-3.
15. Sarrazin, C., et al., Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Zeitschrift Fur Gastroenterologie, 2010. 48(2): p. 289-351.
16. Ackerman, Z., E. Ackerman, and O. Paltiel, Intrafamilial transmission of hepatitis C virus: a systematic review. Journal of Viral Hepatitis, 2000. 7(2): p. 93-103.
17. Orlando, R. and F. Lirussi, Hepatitis C virus infection: sexual or non-sexual transmission between spouses? A case report and review of the literature. Infection, 2007. 35(6): p. 465-8.
18. Wiegand, J., et al., Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology, 2006. 43(2): p.
250-6.
19. Boonyarad, V., et al., Interspousal transmission of hepatitis C in Thailand. J Gastroenterol, 2003. 38(11): p. 1053-9.
20. Kao, J.H., et al., Low incidence of hepatitis C virus transmission between spouses: a prospective study. J Gastroenterol Hepatol, 2000. 15(4): p. 391-5.
21. Qureshi, H., et al., HCV exposure in spouses of the index cases. J Pak Med Assoc, 2007. 57(4): p. 175-7.
22. Alavian, S.M., A shield against a monster: Hepatitis C in hemodialysis patients.
World J Gastroenterol, 2009. 15(6): p. 641-6.
23. Mailliard, M.E., et al., Outcomes of a patient-to-patient outbreak of genotype 3a hepatitis C. Hepatology, 2009. 50(2): p. 361-8.
24. Atlas, S.J., et al., Patient-Physician Connectedness and Quality of Primary Care.
Annals of Internal Medicine, 2009. 150(5): p. 325-+.
25. Bronowicki, J.P., et al., Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med, 1997. 337(4): p. 237-40.
26. Wenzel, R.P. and M.B. Edmond, Patient-to-patient transmission of hepatitis C virus.
Annals of Internal Medicine, 2005. 142(11): p. 940-1.
27. Kubitschke, A., et al., [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. Internist (Berl), 2007. 48(10): p. 1165-72.
28. Sulkowski, M.S. and D.L. Thomas, Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clinical Infectious Diseases, 2005. 40: p. S263-S269.
29. Hoofnagle, J.H., Hepatitis C: the clinical spectrum of disease. Hepatology, 1997. 26(3 Suppl 1): p. 15S-20S.
30. Wedemeyer, H., et al., Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology, 2004. 39(5): p. 1201-3.
31. Deterding, K., et al., The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Zeitschrift Fur Gastroenterologie, 2009. 47(6): p. 531-40.
32. Hoofnagle, J.H., Course and outcome of hepatitis C. Hepatology, 2002. 36(5 Suppl 1):
p. S21-9.
33. Seeff, L.B., Natural history of chronic hepatitis C. Hepatology, 2002. 36(5 Suppl 1):
p. S35-46.
34. Caruntu, F.A. and L. Benea, Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis, 2006. 15(3): p. 249-56.
35. Maheshwari, A., S. Ray, and P.J. Thuluvath, Acute hepatitis C. Lancet, 2008.
372(9635): p. 321-32.
36. Perz, J.F., et al., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 2006. 45(4):
p. 529-38.
37. Poynard, T., P. Bedossa, and P. Opolon, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997. 349(9055): p. 825-32.
38. Freeman, A.J., et al., Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 2001. 34(4 Pt 1): p. 809-16.
39. Pessione, F., et al., Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology, 1998. 27(6): p. 1717-22.
40. Ghany, M.G., et al., Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003. 124(1): p. 97-104.
41. Ryder, S.D., et al., Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut, 2004. 53(3): p. 451-5.
42. Hui, C.K., et al., A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. Journal of Hepatology, 2003. 38(4): p. 511-7.
43. Adinolfi, L.E., et al., Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.
Hepatology, 2001. 33(6): p. 1358-64.
44. Thein, H.H., et al., Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology, 2008.
48(2): p. 418-31.
45. Moradpour, D., F. Penin, and C.M. Rice, Replication of hepatitis C virus. Nat Rev Microbiol, 2007. 5(6): p. 453-63.
46. Feld, J.J. and J.H. Hoofnagle, Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 2005. 436(7053): p. 967-72.
47. Manns, M.P., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 2001. 358(9286): p. 958-65.
48. Moradpour, D. and H.E. Blum, A primer on the molecular virology of hepatitis C.
Liver Int, 2004. 24(6): p. 519-25.
49. Simmonds, P., et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005. 42(4): p. 962-73.
50. Murphy, D., et al., A new genotype of hepatitis C virus originating from central Africa. Hepatology, 2007. 46(4): p. 623a-623a.
51. Pawlotsky, J.M., Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis, 2003. 7(1): p. 45-66.
52. Robertson, B., et al., Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization.
International Committee on Virus Taxonomy. Archives of Virology, 1998. 143(12): p.
2493-503.
53. Gosert, R., et al., Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. Journal of Virology, 2003. 77(9): p.
5487-92.
54. Steinmann, E., et al., Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog, 2007. 3(7): p. e103.
55. Agnello, V., et al., Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A, 1999. 96(22): p. 12766-71.
56. Barth, H., et al., Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. Journal of Biological Chemistry, 2003. 278(42):
p. 41003-12.
57. Basu, A., et al., Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. Journal of Virology, 2007. 81(8): p. 3933-41.
58. Pileri, P., et al., Binding of hepatitis C virus to CD81. Science, 1998. 282(5390): p.
938-41.
59. Scarselli, E., et al., The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo Journal, 2002. 21(19): p. 5017-25.
60. Blanchard, E., et al., Hepatitis C virus entry depends on clathrin-mediated endocytosis. Journal of Virology, 2006. 80(14): p. 6964-72.
61. Evans, M.J., et al., Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007. 446(7137): p. 801-5.
62. Ploss, A., et al., Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature, 2009. 457(7231): p. 882-6.
63. El-Hage, N. and G. Luo, Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol, 2003. 84(Pt 10): p. 2761-9.
64. Shimoike, T., et al., Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. Journal of Virology, 1999. 73(12): p. 9718-25.
65. Tanaka, Y., et al., Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5' untranslated region of the viral genome.
Virology, 2000. 270(1): p. 229-36.
66. Mackenzie, J.M. and E.G. Westaway, Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. Journal of Virology, 2001. 75(22): p. 10787-99.
67. Gastaminza, P., S.B. Kapadia, and F.V. Chisari, Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. Journal of Virology, 2006. 80(22): p. 11074-81.
68. Huang, H., et al., Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A, 2007. 104(14): p. 5848-53.
69. von Hahn, T., et al., Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Rev Gastroenterol Hepatol, 2010. 4(1): p. 63-79.
70. Mercer, D.F., et al., Hepatitis C virus replication in mice with chimeric human livers.
Nat Med, 2001. 7(8): p. 927-33.
71. Lohmann, V., et al., Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999. 285(5424): p. 110-3.
72. Bartenschlager, R., M. Frese, and T. Pietschmann, Novel insights into hepatitis C virus replication and persistence. Advances in Virus Research, Vol 51, 2004. 63: p. 71-180.
73. Blight, K.J., J.A. McKeating, and C.M. Rice, Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. Journal of Virology, 2002. 76(24): p. 13001-14.
74. Bartosch, B., J. Dubuisson, and F.L. Cosset, Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med, 2003.
197(5): p. 633-42.
75. Drummer, H.E., A. Maerz, and P. Poumbourios, Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett, 2003. 546(2-3): p. 385-90.
76. Hsu, M., et al., Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A, 2003. 100(12): p. 7271-6.
77. Wakita, T., et al., Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med, 2005. 11(7): p. 791-6.
78. Zhong, J., et al., Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A, 2005. 102(26): p. 9294-9.
79. Lindenbach, B.D., et al., Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A, 2006. 103(10): p. 3805-9.
80. Pietschmann, T., et al., Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A, 2006.
103(19): p. 7408-13.
81. Koutsoudakis, G., et al., Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. Journal of Virology, 2006. 80(11): p.
5308-20.
82. Koutsoudakis, G., et al., The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. Journal of Virology, 2007. 81(2): p. 588-98.
83. Matsuura, Y., et al., Characterization of pseudotype VSV possessing HCV envelope proteins. Virology, 2001. 286(2): p. 263-75.
84. Schaller, T., et al., Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. Journal of Virology, 2007. 81(9): p.
4591-603.
85. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network.
BJOG, 2001. 108(4): p. 371-7.
86. Kumar, R.M. and S. Shahul, Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. Journal of Hepatology, 1998. 29(2): p. 191-7.
87. Nduati, R., et al., Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA, 2000. 283(9): p. 1167-74.
88. Rousseau, C.M., et al., Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis, 2003. 187(5): p. 741-7.
89. Menard, S., et al., Developmental switch of intestinal antimicrobial peptide expression. J Exp Med, 2008. 205(1): p. 183-93.
90. Auvynet, C. and Y. Rosenstein, Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. Febs Journal, 2009. 276(22): p. 6497-508.
91. Pathan, F.K., D.A. Venkata, and S.K. Panguluri, Recent patents on antimicrobial peptides. Recent Pat DNA Gene Seq, 2010. 4(1): p. 10-6.
92. Legrand, D., et al., Lactoferrin structure and functions. Adv Exp Med Biol, 2008. 606:
p. 163-94.
93. Sanchez, L., et al., Concentration of lactoferrin and transferrin throughout lactation in cow's colostrum and milk. Biol Chem Hoppe Seyler, 1988. 369(9): p. 1005-8.
94. Haupt, H. and S. Baudner, [Isolation and crystallization of lactoferrin from human colostrum (author's transl)]. Hoppe Seylers Z Physiol Chem, 1973. 354(8): p. 944-8.
95. Farnaud, S. and R.W. Evans, Lactoferrin--a multifunctional protein with antimicrobial properties. Mol Immunol, 2003. 40(7): p. 395-405.
96. Kanwar, J.R., et al., Molecular and biotechnological advances in milk proteins in relation to human health. Curr Protein Pept Sci, 2009. 10(4): p. 308-38.
97. Moriuchi, M. and H. Moriuchi, A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol, 2001. 166(6): p.
4231-6.
98. Ikeda, M., et al., Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun, 1998. 245(2): p. 549-53.
99. Ikeda, M., et al., Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res, 2000. 66(1): p. 51-63.
100. El-Fakharany, E.M., et al., Potential activity of camel milk-amylase and lactoferrin against hepatitis C virus infectivity in hepG2 and lymphocytes. Hepatitis Monthly, 2008. 8(2): p. 101-109.
101. Yi, M., et al., Hepatitis C virus envelope proteins bind lactoferrin. Journal of Virology, 1997. 71(8): p. 5997-6002.
102. Abe, K., et al., Tandem repeats of lactoferrin-derived anti-hepatitis C virus peptide enhance antiviral activity in cultured human hepatocytes. Microbiol Immunol, 2007.
51(1): p. 117-25.
103. Nozaki, A., et al., Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. Journal of Biological Chemistry, 2003. 278(12): p. 10162-73.
104. Tamura, K., et al., Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. Microbes Infect, 2005. 7(1): p. 29-40.
105. Tanaka, K., et al., Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res, 1999. 90(4): p. 367-71.
106. Iwasa, M., et al., Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. American Journal of Gastroenterology, 2002. 97(3): p. 766-7.
107. Ishii, K., et al., Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res, 2003. 25(3): p. 226-233.
108. Okada, S., et al., Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res, 2002. 93(9): p. 1063-9.
109. Ishibashi, Y., et al., Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. Hepatol Res, 2005.
32(4): p. 218-23.
110. Ueno, H., et al., Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Sci, 2006. 97(10): p. 1105-10.
111. Zhao, X.P., et al., Infectivity and risk factors of hepatitis C virus transmission through sexual contact. J Tongji Med Univ, 1995. 15(3): p. 147-50.
112. Danta, M., et al., Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids, 2007. 21(8): p. 983-91.
113. Gotz, H.M., et al., A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. Aids, 2005.
19(9): p. 969-74.
114. Gambotti, L., et al., Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill, 2005. 10(5): p. 115-7.
115. Leruez-Ville, M., et al., Detection of hepatitis C virus in the semen of infected men.
Lancet, 2000. 356(9223): p. 42-3.
116. McKee, T.A., et al., Risks for transmission of hepatitis C virus during artificial insemination. Fertility and Sterility, 1996. 66(1): p. 161-3.
117. Fiore, R.J., et al., Detection of HCV RNA in serum and seminal fluid from HIV-1 co-infected intravenous drug addicts. J Med Virol, 1995. 46(4): p. 364-7.
118. Kotwal, G.J., V.K. Rustgi, and B.M. Baroudy, Detection of hepatitis C virus-specific antigens in semen from non-A, non-B hepatitis patients. Dig Dis Sci, 1992. 37(5): p.
641-4.
119. Fried, M.W., et al., Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. Gastroenterology, 1992. 102(4 Pt 1): p. 1306-8.
120. Semprini, A.E., et al., Absence of hepatitis C virus and detection of hepatitis G virus/GB virus C RNA sequences in the semen of infected men. J Infect Dis, 1998.
177(4): p. 848-54.
121. Münch, J., et al., Semen-derived amyloid fibrils drastically enhance HIV infection.
Cell, 2007. 131(6): p. 1059-71.
122. Hong, S., et al., Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. Journal of Virology, 2009. 83(14): p. 6995-7003.
123. Hauber, I., et al., The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci U S A, 2009. 106(22): p. 9033-8.
124. Yang, C.S., P. Maliakal, and X. Meng, Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol, 2002. 42: p. 25-54.
125. Cabrera, C., R. Artacho, and R. Gimenez, Beneficial effects of green tea--a review. J Am Coll Nutr, 2006. 25(2): p. 79-99.
126. Ehrnhoefer, D.E., et al., EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol, 2008. 15(6): p. 558-66.
127. Zuo, G., et al., Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res, 2007. 76(1): p. 86-92.
128. Lindenbach, B.D., et al., Complete replication of hepatitis C virus in cell culture.
Science, 2005. 309(5734): p. 623-6.
129. Karber, G., [On so-called oxide-wax, a solid polyethyleneglycol.]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol, 1951. 212(5-6): p. 509-21.
130. Spearman, C., The proof and measurement of association between two things. By C.
Spearman, 1904. Am J Psychol, 1987. 100(3-4): p. 441-71.
131. Cronin, J., X.Y. Zhang, and J. Reiser, Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther, 2005. 5(4): p. 387-98.
132. Andre, P., et al., Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. Journal of Virology, 2002. 76(14): p. 6919-28.
133. Zhang, J., et al., CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. Journal of Virology, 2004. 78(3): p. 1448-55.
134. Allen, R.D. and T.K. Roberts, Role of spermine in the cytotoxic effects of seminal plasma. Am J Reprod Immunol Microbiol, 1987. 13(1): p. 4-8.
135. Fiore, J.R., et al., The use of serum-free medium delays, but does not prevent, the cytotoxic effects of seminal plasma in lymphocyte cultures: implications for studies on HIV infection. New Microbiol, 1997. 20(4): p. 339-44.
136. Song, J.M., K.H. Lee, and B.L. Seong, Antiviral effect of catechins in green tea on influenza virus. Antiviral Res, 2005. 68(2): p. 66-74.